• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CVS Health appoints Michael F. Mahoney to its Board of Directors

    9/21/23 6:45:00 AM ET
    $BSX
    $CVS
    Medical/Dental Instruments
    Health Care
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $BSX alert in real time by email

    WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE:BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1.

    CVS Health (PRNewsFoto/CVS Health)

    "Mike's focus throughout his career – to drive improvements in health outcomes and increase access to care – align with our mission at CVS Health," said CVS Health President and CEO Karen S. Lynch. "Adding a well-respected health care leader to our Board demonstrates our continued focus on strengthening our engagement with consumers to improve their health and well-being."

    Mahoney became the CEO of Boston Scientific Corporation in 2012 and became Chairman of the company's Board of Directors in 2016. With more than 45,000 global employees, Boston Scientific reaches over 33 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, structural heart, electrophysiology, endoscopy, neuromodulation, urology, and women's health.

    "We're extremely pleased to have Mike join the Board," said Roger N. Farah, Independent Chair of the Board of CVS Health. "His knowledge and insight will be a tremendous asset, as will his background in leading the development of innovative solutions for patients."

    Mahoney's career spans more than 25 years of success building market-leading medical device, capital equipment and health care IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics division of Johnson & Johnson. Mahoney previously was President and CEO of Global Healthcare Exchange, a leading medical supply chain solutions company. For the first 12 years of his career, he advanced through a series of leadership roles at General Electric Medical Systems, including as General Manager of its Healthcare Information Technology business.

    "CVS Health and Boston Scientific share many common goals, with a primary focus on making a real difference for the people and patients we serve," Mahoney said. "I hope that my experience within the health care industry will help me work with the Board and the management team to support and advance CVS Health's strategy."

    Mahoney serves on the Board of the Boys & Girls Club of Boston and as the chair of the Board of Governors of the Boston College Chief Executives Club. He previously served on the Board of Directors of Baxter International Inc., a multinational health care company. He earned his B.B.A. in Finance from the University of Iowa and his M.B.A. from Wake Forest University. He is married and has three children.

    About CVS Health

    CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

    Media contact

    Ethan Slavin

    860-273-6095

    [email protected]

    Investor contact

    Larry McGrath

    800-201-0938

    [email protected] 

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-appoints-michael-f-mahoney-to-its-board-of-directors-301934025.html

    SOURCE CVS Health

    Get the next $BSX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BSX
    $CVS

    CompanyDatePrice TargetRatingAnalyst
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    CVS Health Corporation
    $CVS
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    CVS Health Corporation
    $CVS
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    CVS Health Corporation
    $CVS
    1/30/2025Hold → Buy
    Edward Jones
    Boston Scientific Corporation
    $BSX
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    CVS Health Corporation
    $CVS
    12/3/2024$66.00Hold → Buy
    Deutsche Bank
    CVS Health Corporation
    $CVS
    11/18/2024$60.00 → $66.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $BSX
    $CVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 1, 2024 - FDA Roundup: March 1, 2024

      For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

      3/1/24 4:00:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care